<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04266106</url>
  </required_header>
  <id_info>
    <org_study_id>MMC-2019-56</org_study_id>
    <nct_id>NCT04266106</nct_id>
  </id_info>
  <brief_title>Probiotics and Recovery From Gastrointestinal Surgery - 2</brief_title>
  <acronym>PROGRESS-2</acronym>
  <official_title>Effect of Perioperative Probiotics on Clinical Outcomes of Patients Undergoing Major Abdominal Operation in Community Settings - 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jan Franko, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SuperBio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MercyOne Des Moines Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective randomized trial is designed to test a pragmatic simple intervention in a
      community hospital. The trial will test the hypothesis whether patient recovery after a major
      elective abdominal operation can be improved and/or accelerated with postoperative use of
      probiotics.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>up to 2 months</time_frame>
    <description>Functional Assessment of Cancer Therapy (FACT) G7 score: higher value corresponds with better QoL, range 0-28 points</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Surgical Recovery</condition>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SuperBio probiotic</intervention_name>
    <description>One capsule po BID for 28 days</description>
    <arm_group_label>probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One capsule po BID for 28 days</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged ≥18 years undergoing elective major abdominal operation

          -  Functional GI tract expected after operation

        Exclusion Criteria:

          -  Current episode of acute necrotizing pancreatitis as defined by surgeon

          -  Palliative decompressive GI tube

          -  Life expectancy ≤ 6 months

          -  Systemic immune-mediated disease active requiring systemic therapy:

          -  Prednisone ≥20 mg QD

          -  IV immunoglobulins

          -  Anti-rejection medication

          -  Presence of functional transplanted organ

          -  Systemic collagen-related disease treated with immunomodulating agents, including
             rheumatoid arthritis, SLE, scleroderma, etc.

          -  Topical chemotherapy or corticosteroids, and chemotherapy applied during operation are
             allowed

          -  Patient taking probiotics, synbiotics, or cobiotics as part of their lifestyle

          -  Need for full systemic anticoagulation postoperatively.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Franko</last_name>
    <role>Principal Investigator</role>
    <affiliation>MercyOne Des Moines Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Franko</last_name>
    <phone>5152473266</phone>
    <email>jfranko@mercydesmoines.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>MercyOne Des Moines Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Franko J, Raman S, Krishnan N, Frankova D, Tee MC, Brahmbhatt R, Goldman CD, Weigel RJ. Randomized Trial of Perioperative Probiotics Among Patients Undergoing Major Abdominal Operation. J Am Coll Surg. 2019 Dec;229(6):533-540.e1. doi: 10.1016/j.jamcollsurg.2019.09.002. Epub 2019 Sep 25.</citation>
    <PMID>31562911</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2020</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>MercyOne Des Moines Medical Center</investigator_affiliation>
    <investigator_full_name>Jan Franko, MD</investigator_full_name>
    <investigator_title>Chair of Surgical Oncology</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

